<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36207571</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>25</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-7479</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics</Title><ISOAbbreviation>Neurotherapeutics</ISOAbbreviation></Journal><ArticleTitle>Axon Biology in ALS: Mechanisms of Axon Degeneration and Prospects for Therapy.</ArticleTitle><Pagination><StartPage>1133</StartPage><EndPage>1144</EndPage><MedlinePgn>1133-1144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13311-022-01297-6</ELocationID><Abstract><AbstractText>This review addresses the longstanding debate over whether amyotrophic lateral sclerosis (ALS) is a 'dying back' or 'dying forward' disorder in the light of new gene identifications and the increased understanding of mechanisms of action for previously identified ALS genes. While the topological pattern of pathology in animal models, and more anecdotally in patients is indeed 'dying back', this review discusses how this fits with the fact that many of the major initiating events are thought to occur within the soma. It also discusses how widely varying ALS risk factors, including some impacting axons directly, may combine to drive a common pathway involving TAR DNA binding protein 43 (TDP-43) and neuromuscular junction (NMJ) denervation. The emerging association between sterile alpha and TIR motif-containing 1 (SARM1), a protein so far mostly associated with axon degeneration, and sporadic ALS is another major theme. The strengths and limitations of the current evidence supporting an association are considered, along with ways in which SARM1 could become activated in ALS. The final section addresses SARM1-based therapies along with the prospects for targeting other axonal steps in ALS pathogenesis.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Coleman</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><Identifier Source="ORCID">0000-0002-9354-532X</Identifier><AffiliationInfo><Affiliation>John van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Robinson Way, Cambridge, CB2 0PY, UK. mc469@cam.ac.uk.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurotherapeutics</MedlineTA><NlmUniqueID>101290381</NlmUniqueID><ISSNLinking>1878-7479</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051186">Armadillo Domain Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003598">Cytoskeletal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051186" MajorTopicYN="N">Armadillo Domain Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003598" MajorTopicYN="N">Cytoskeletal Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001369" MajorTopicYN="N">Axons</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001695" MajorTopicYN="N">Biology</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Axon degeneration</Keyword><Keyword MajorTopicYN="N">Axonal transport</Keyword><Keyword MajorTopicYN="N">NAD</Keyword><Keyword MajorTopicYN="N">NMNAT2</Keyword><Keyword MajorTopicYN="N">Programmed axon death</Keyword><Keyword MajorTopicYN="N">SARM1</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>10</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>7</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36207571</ArticleId><ArticleId IdType="pmc">PMC9587191</ArticleId><ArticleId IdType="doi">10.1007/s13311-022-01297-6</ArticleId><ArticleId IdType="pii">10.1007/s13311-022-01297-6</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Eisen A. The dying forward hypothesis of ALS: tracing its history. Brain Sci. 2021;11:300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7997258</ArticleId><ArticleId IdType="pubmed">33673524</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Tennant P, et al. Amyotrophic lateral sclerosis is a distal axonopathy: evidence in mice and man. Exp Neurol. 2004;185:232&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">14736504</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterloh JM, Yang J, Rooney TM, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science. 2012;337:481&#x2013;484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5225956</ArticleId><ArticleId IdType="pubmed">22678360</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerdts J, Summers DW, Sasaki Y, et al. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci. 2013;33:13569&#x2013;13580.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3742939</ArticleId><ArticleId IdType="pubmed">23946415</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Jackson O, Pipis M, et al. Enrichment of SARM1 alleles encoding variants with constitutively hyperactive NADase in patients with ALS and other motor nerve disorders. eLife. 2021;10:e70905.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8735862</ArticleId><ArticleId IdType="pubmed">34796871</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloom AJ, Mao X, Strickland A, et al. Constitutively active SARM1 variants that induce neuropathy are enriched in ALS patients. Mol Neurodegeneration. 2022;17:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8739729</ArticleId><ArticleId IdType="pubmed">34991663</ArticleId></ArticleIdList></Reference><Reference><Citation>Loreto A, Angeletti C, Gu W, et al. Neurotoxin-mediated potent activation of the axon degeneration regulator SARM1. eLife. 2021;10:e72823.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8758145</ArticleId><ArticleId IdType="pubmed">34870595</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu T, Zhu J, Strickland A, et al. Neurotoxins subvert the allosteric activation mechanism of SARM1 to induce neuronal loss. Cell Rep. 2021;37:109872.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8638332</ArticleId><ArticleId IdType="pubmed">34686345</ArticleId></ArticleIdList></Reference><Reference><Citation>Crawford CL, Antoniou C, Komarek L, et al. SARM1 depletion slows axon degeneration in a CNS model of neurotropic viral infection. Front Mol Neurosci. 2022;15:860410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9043327</ArticleId><ArticleId IdType="pubmed">35493328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundaramoorthy V, Green D, Locke K, et al. Novel role of SARM1 mediated axonal degeneration in the pathogenesis of rabies. PLoS Pathog. 2020;16:e1008343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7048299</ArticleId><ArticleId IdType="pubmed">32069324</ArticleId></ArticleIdList></Reference><Reference><Citation>Szretter KJ, Samuel MA, Gilfillan S, et al. The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile virus pathogenesis. J Virol. 2009;83:9329&#x2013;9338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2738257</ArticleId><ArticleId IdType="pubmed">19587044</ArticleId></ArticleIdList></Reference><Reference><Citation>Blakemore WF, Cavanagh JB. &#x201c;Neuroaxonal dystrophy&#x201d; occurring in an experimental, &#x201c;dying back&#x201d; process in the rat. Brain. 1969;92:789&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">5364009</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouldin TW, Cavanagh JB. Organophosphorous neuropathy: I.A teased-fiber study of the spatio-temporal spread of axonal degeneration. Am J Path. 1979;94:241&#x2013;252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2042239</ArticleId><ArticleId IdType="pubmed">426027</ArticleId></ArticleIdList></Reference><Reference><Citation>deF. Webster H. Transient, focal accumulation of axonal mitochondria during the early stages of Wallerian degeneration. J Cell Biol. 1962;12:361&#x2013;383.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2106025</ArticleId><ArticleId IdType="pubmed">14005486</ArticleId></ArticleIdList></Reference><Reference><Citation>Beirowski B, Berek L, Adalbert R, et al. Quantitative and qualitative analysis of Wallerian degeneration using restricted axonal labelling in YFP-H mice. J Neurosci Methods. 2004;134:23&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mi W. The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain. 2004;128:405&#x2013;416.</Citation><ArticleIdList><ArticleId IdType="pubmed">15644421</ArticleId></ArticleIdList></Reference><Reference><Citation>Beirowski B, N&#xf3;gr&#xe1;di A, Babetto E, et al. Mechanisms of axonal spheroid formation in central nervous system Wallerian degeneration. J Neuropathol Exp Neurol. 2010;69:455&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">20418780</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaefer AM, Sanes JR, Lichtman JW. A compensatory subpopulation of motor neurons in a mouse model of amyotrophic lateral sclerosis. J Comp Neurol. 2005;490:209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pubmed">16082680</ArticleId></ArticleIdList></Reference><Reference><Citation>Reyes NA, Fisher JK, Austgen K, et al. Blocking the mitochondrial apoptotic pathway preserves motor neuron viability and function in a mouse model of amyotrophic lateral sclerosis. J Clin Invest. 2010;120:3673&#x2013;3679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2947232</ArticleId><ArticleId IdType="pubmed">20890041</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer RC, Chami AA, de Assis DR, et al. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: a resolution in sight? Brain. 2019;142:1176&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould TW. Complete dissociation of motor neuron death from motor dysfunction by Bax deletion in a mouse model of ALS. J Neurosci. 2006;26:8774&#x2013;8786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6674380</ArticleId><ArticleId IdType="pubmed">16928866</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson J, Sanelli T, Xiao S, et al. Lack of TDP-43 abnormalities in mutant SOD1 transgenic mice shows disparity with ALS. Neurosci Lett. 2007;420:128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pubmed">17543992</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato-Yamada Y, Strickland A, Sasaki Y, et al. SARM1 promotes axonal, synaptic, and mitochondrial pathologies in Charcot-Marie-Tooth disease type 2A. Neuroscience. 2022.&#xa0;http://biorxiv.org/lookup/doi/10.1101/2022.05.17.492364. Accessed 7 Jul 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.05.17.492364</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez-Moreno R, et al. Characterization of early pathogenesis in the SOD1 G93A mouse model of ALS: part II, results and discussion. Brain Behav. 2013;3:431&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869683</ArticleId><ArticleId IdType="pubmed">24381813</ArticleId></ArticleIdList></Reference><Reference><Citation>Vinsant S, Mansfield C, Jimenez-Moreno R, et al. Characterization of early pathogenesis in the SOD1 G93A mouse model of ALS: part I, background and methods. Brain Behav. 2013;3:335&#x2013;350.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3869677</ArticleId><ArticleId IdType="pubmed">24381807</ArticleId></ArticleIdList></Reference><Reference><Citation>Martineau &#xc9;, Di Polo A, Vande Velde C, et al. Dynamic neuromuscular remodeling precedes motor-unit loss in a mouse model of ALS. eLife. 2018;7:e41973.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6234026</ArticleId><ArticleId IdType="pubmed">30320556</ArticleId></ArticleIdList></Reference><Reference><Citation>Morii H, Shiraishi-Yamaguchi Y, Mori N. SCG10, a microtubule destabilizing factor, stimulates the neurite outgrowth by modulating microtubule dynamics in rat hippocampal primary cultured neurons. J Neurobiol. 2006;66:1101&#x2013;1114.</Citation><ArticleIdList><ArticleId IdType="pubmed">16838365</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein R, Matthews K, Lo L-C, et al. The NGF-inducible SCGlO mRNA encodes a novel membrane-bound protein present in growth cones and abundant in developing neurons. Neuron. 1988;1:463&#x2013;476.</Citation><ArticleIdList><ArticleId IdType="pubmed">3272176</ArticleId></ArticleIdList></Reference><Reference><Citation>Krus KL, Strickland A, Yamada Y, et al. Loss of Stathmin-2, a hallmark of TDP-43-associated ALS, causes motor neuropathy. Neuroscience. 2022.&#xa0;http://biorxiv.org/lookup/doi/10.1101/2022.03.13.484188. Accessed 15 Mar 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.03.13.484188</ArticleId><ArticleId IdType="pmc">PMC9327139</ArticleId><ArticleId IdType="pubmed">35767949</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco G, Ribchester RR, et al. Confocal microendoscopy of neuromuscular synapses in living mice. In: Auwerx J, Brown SD, Justice M, et al., editors. Current Protocols in Mouse Biology. Hoboken, NJ, USA: John Wiley &amp; Sons, Inc.; 2012. p. mo110144. https://onlinelibrary.wiley.com/doi/10.1002/9780470942390.mo110144. Accessed 4 Jul 2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470942390.mo110144</ArticleId><ArticleId IdType="pubmed">26069002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillingwater TH, Thomson D, Mack TGA, et al. Age-dependent synapse withdrawal at axotomised neuromuscular junctions in Wld s mutant and Ube4b/Nmnat transgenic mice. J Physiol. 2002;543:739&#x2013;755.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2290540</ArticleId><ArticleId IdType="pubmed">12231635</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack TGA, Reiner M, Beirowski B, et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci. 2001;4:1199&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pubmed">11770485</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Ribchester RR, Coleman MP. Sarm1 Deletion, but Not Wld S, Confers lifelong rescue in a mouse model of severe axonopathy. Cell Rep. 2017;21:10&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5640801</ArticleId><ArticleId IdType="pubmed">28978465</ArticleId></ArticleIdList></Reference><Reference><Citation>Adalbert R, N&#xf3;gr&#xe1;di A, Szab&#xf3; A, et al. The slow Wallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy. Eur J Neurosci. 2006;24:2163&#x2013;2168.</Citation><ArticleIdList><ArticleId IdType="pubmed">17074042</ArticleId></ArticleIdList></Reference><Reference><Citation>Moon LDF. Chromatolysis: do injured axons regenerate poorly when ribonucleases attack rough endoplasmic reticulum, ribosomes and RNA? Devel Neurobio. 2018;78:1011&#x2013;1024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6334169</ArticleId><ArticleId IdType="pubmed">30027624</ArticleId></ArticleIdList></Reference><Reference><Citation>Beirowski B, Babetto E, Coleman MP, et al. The Wld S gene delays axonal but not somatic degeneration in a rat glaucoma model. Eur J Neurosci. 2008;28:1166&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">18783366</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielson JL, Strong MK, Steward O. A reassessment of whether cortical motor neurons die following spinal cord injury. J Comp Neurol. 2011;519:2852&#x2013;2869.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3916191</ArticleId><ArticleId IdType="pubmed">21618218</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin N, Jaubert J, Gounon P, et al. A missense mutation in Tbce causes progressive motor neuronopathy in mice. Nat Genet. 2002;32:443&#x2013;447.</Citation><ArticleIdList><ArticleId IdType="pubmed">12389029</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, Sanes JR, Coleman MP, et al. Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol. 2003;13:669&#x2013;673.</Citation><ArticleIdList><ArticleId IdType="pubmed">12699624</ArticleId></ArticleIdList></Reference><Reference><Citation>Sferra A, Baillat G, Rizza T, et al. TBCE mutations cause early-onset progressive encephalopathy with distal spinal muscular atrophy. The American Journal of Human Genetics. 2016;99:974&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5065657</ArticleId><ArticleId IdType="pubmed">27666369</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C, Calvaresi N, Chiveri L, et al. Early vacuolization and mitochondrial damage in motor neurons of FALS mice are not associated with apoptosis or with changes in cytochrome oxidase histochemical reactivity. J Neurol Sci. 2001;191:25&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11676989</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Kim E, Duffy A, et al. TDP-43 gains function due to perturbed autoregulation in a Tardbp knock-in mouse model of ALS-FTD. Nat Neurosci. 2018;21:552&#x2013;563.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5884423</ArticleId><ArticleId IdType="pubmed">29556029</ArticleId></ArticleIdList></Reference><Reference><Citation>Fumagalli L, Young FL, Boeynaems S, De Decker M, Mehta AR, Swijsen A, Fazal R, Guo W, Moisse M, Beckers J, Dedeene L. C9orf72-derived arginine-containing dipeptide repeats associate with axonal transport machinery and impede microtubule-based motility. Sci Adv. 2021;21:eabg3013.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034861</ArticleId><ArticleId IdType="pubmed">33837088</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagano S, Jinno J, Abdelhamid RF, et al. TDP-43 transports ribosomal protein mRNA to regulate axonal local translation in neuronal axons. Acta Neuropathol. 2020;140:695&#x2013;713.</Citation><ArticleIdList><ArticleId IdType="pubmed">32803350</ArticleId></ArticleIdList></Reference><Reference><Citation>Sleigh JN, Tosolini AP, Gordon D, et al. Mice carrying ALS mutant TDP-43, but not mutant FUS, display in vivo defects in axonal transport of signaling endosomes. Cell Rep. 2020;30:3655&#x2013;3662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7090381</ArticleId><ArticleId IdType="pubmed">32187538</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, L&#xf3;pez-Erauskin J, Baughn MW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F, et al. ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta AR, Gregory JM, Dando O, et al. Mitochondrial bioenergetic deficits in C9orf72 amyotrophic lateral sclerosis motor neurons cause dysfunctional axonal homeostasis. Acta Neuropathol. 2021;141:257&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7847443</ArticleId><ArticleId IdType="pubmed">33398403</ArticleId></ArticleIdList></Reference><Reference><Citation>Baron DM, Fenton AR, Saez-Atienzar S, et al. ALS-associated KIF5A mutations abolish autoinhibition resulting in a toxic gain of function. Cell Rep. 2022;39:110598.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9134378</ArticleId><ArticleId IdType="pubmed">35385738</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin M, Iyadurai SJ, Gassman A, et al. Cytoplasmic dynein, the dynactin complex, and kinesin are interdependent and essential for fast axonal transport. Molecular Biol Cell. 1999;10:3717&#x2013;3728.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC25669</ArticleId><ArticleId IdType="pubmed">10564267</ArticleId></ArticleIdList></Reference><Reference><Citation>Figlewicz DA, Krizus A, Martinoli MG, et al. Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet. 1994;3:1757&#x2013;1761.</Citation><ArticleIdList><ArticleId IdType="pubmed">7849698</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu G, Ou S, Cui H, et al. Head injury and amyotrophic lateral sclerosis: a meta-analysis. Neuroepidemiology. 2021;55:11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">33621971</ArticleId></ArticleIdList></Reference><Reference><Citation>Milde S, Adalbert R, Elaman MH, et al. Axonal transport declines with age in two distinct phases separated by a period of relative stability. Neurobiol Aging. 2015;36:971&#x2013;981.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4321880</ArticleId><ArticleId IdType="pubmed">25443288</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothstein JD, Dykes-Hoberg M, Pardo CA, et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron. 1996;16:675&#x2013;686.</Citation><ArticleIdList><ArticleId IdType="pubmed">8785064</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman MP, Hoke A. Programmed axon degeneration: from mouse to mechanism to medicine. Nat Rev Neurosci. 2020;21:183&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8926152</ArticleId><ArticleId IdType="pubmed">32152523</ArticleId></ArticleIdList></Reference><Reference><Citation>Essuman K, Summers DW, Sasaki Y, et al. The SARM1 Toll/Interleukin-1 receptor domain possesses intrinsic NAD + cleavage activity that promotes pathological axonal degeneration. Neuron. 2017;93:1334&#x2013;1343.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284238</ArticleId><ArticleId IdType="pubmed">28334607</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao ZY, Xie XJ, Li WH, et al. A cell-permeant mimetic of NMN activates SARM1 to produce cyclic ADP-ribose and induce non-apoptotic cell death. iScience. 2019;15:452&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6531917</ArticleId><ArticleId IdType="pubmed">31128467</ArticleId></ArticleIdList></Reference><Reference><Citation>Angeletti C, Amici A, Gilley J, et al. SARM1 is a multi-functional NAD(P)ase with prominent base exchange activity, all regulated bymultiple physiologically relevant NAD metabolites. iScience. 2022;25:103812.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8844822</ArticleId><ArticleId IdType="pubmed">35198877</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xfc;hn FJP, L&#xfc;ckhoff A. Sites of the NUDT9-H Domain critical for ADP-ribose activation of the cation channel TRPM2. J Biol Chem. 2004;279:46431&#x2013;46437.</Citation><ArticleIdList><ArticleId IdType="pubmed">15347676</ArticleId></ArticleIdList></Reference><Reference><Citation>Figley MD, Gu W, Nanson JD, et al. SARM1 is a metabolic sensor activated by an increased NMN/NAD+ ratio to trigger axon degeneration. Neuron. 2021;109:1118&#x2013;1136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8174188</ArticleId><ArticleId IdType="pubmed">33657413</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang Y, Liu T, Lee C-H, et al. The NAD+-mediated self-inhibition mechanism of pro-neurodegenerative Sarm1. Nature. 2020. http://www.nature.com/articles/s41586-020-2862-z. Accessed 3 Nov 2020.</Citation><ArticleIdList><ArticleId IdType="pubmed">33053563</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 2010;8:e1000300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811159</ArticleId><ArticleId IdType="pubmed">20126265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Adalbert R, Yu G, et al. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. J Neurosci. 2013;33:13410&#x2013;13424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6705152</ArticleId><ArticleId IdType="pubmed">23946398</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler S, Doan RA, Strickland A, et al. Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice. Brain. 2016;139:3092&#x2013;3108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5840884</ArticleId><ArticleId IdType="pubmed">27797810</ArticleId></ArticleIdList></Reference><Reference><Citation>Turkiew E, Falconer D, Reed N, et al. Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy: Deletion of Sarm1 gene is neuroprotective in two models of peripheral neuropathy. J Peripher Nerv Syst. 2017;22:162&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5585053</ArticleId><ArticleId IdType="pubmed">28485482</ArticleId></ArticleIdList></Reference><Reference><Citation>Huppke P, Wegener E, Gilley J, et al. Homozygous NMNAT2 mutation in sisters with polyneuropathy and erythromelalgia. Exp Neurol. 2019;320:112958.</Citation><ArticleIdList><ArticleId IdType="pubmed">31132363</ArticleId></ArticleIdList></Reference><Reference><Citation>Lukacs M, Gilley J, Zhu Y, et al. Severe biallelic loss-of-function mutations in nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) in two fetuses with fetal akinesia deformation sequence. Exp Neurol. 2019;320:112961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6708453</ArticleId><ArticleId IdType="pubmed">31136762</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilley J, Mayer PR, Yu G, et al. Low levels of NMNAT2 compromise axon development and survival. Hum Mol Genet. 2019;28:448&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">30304512</ArticleId></ArticleIdList></Reference><Reference><Citation>Falk MJ, Zhang Q, Nakamaru-Ogiso E, et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet. 2012;44:1040&#x2013;1045.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454532</ArticleId><ArticleId IdType="pubmed">22842227</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki Y, Kakita H, Kubota S, et al. SARM1 depletion rescues NMNAT1-dependent photoreceptor cell death and retinal degeneration. eLife. 2020;9:e62027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7591247</ArticleId><ArticleId IdType="pubmed">33107823</ArticleId></ArticleIdList></Reference><Reference><Citation>LeWitt PA. Neurotoxicity of the rat poison vacor. N Engl J Med. 1980;302:73&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">6243167</ArticleId></ArticleIdList></Reference><Reference><Citation>SLAGEN Consortium. van Rheenen W, et al. Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016;48:1043&#x2013;1048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556360</ArticleId><ArticleId IdType="pubmed">27455348</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Fang F, Hanby MF, et al. An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry. 2010;81:1324&#x2013;1326.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2988617</ArticleId><ArticleId IdType="pubmed">20861059</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue YC, Feuer R, Cashman N, et al. Enteroviral infection: the forgotten link to amyotrophic lateral sclerosis? Front Mol Neurosci. 2018;11:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5857577</ArticleId><ArticleId IdType="pubmed">29593492</ArticleId></ArticleIdList></Reference><Reference><Citation>Satin ZA, Bayat E. ALS-like disorder in three HIV-positive patients: case series. Case Rep Neurol. 2021;13:59&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7923715</ArticleId><ArticleId IdType="pubmed">33708095</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellmann J, Monette A, Tripathy V, et al. Viral infections exacerbate FUS-ALS phenotypes in iPSC-derived spinal neurons in a virus species-specific manner. Front Cell Neurosci. 2019;13:480.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6817715</ArticleId><ArticleId IdType="pubmed">31695598</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardiman O, Al-Chalabi A, Chio A, et al. Amyotrophic lateral sclerosis. Nat Rev Dis Primers. 2017;3:17071.</Citation><ArticleIdList><ArticleId IdType="pubmed">28980624</ArticleId></ArticleIdList></Reference><Reference><Citation>Julian TH, Glascow N, Barry ADF, et al. Physical exercise is a risk factor for amyotrophic lateral sclerosis: convergent evidence from Mendelian randomisation, transcriptomics and risk genotypes. EBioMedicine. 2021;68:103397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8170114</ArticleId><ArticleId IdType="pubmed">34051439</ArticleId></ArticleIdList></Reference><Reference><Citation>Franz CK, Joshi D, Daley EL, et al. Impact of traumatic brain injury on amyotrophic lateral sclerosis: from bedside to bench. J Neurophysiol. 2019;122:1174&#x2013;1185.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6766734</ArticleId><ArticleId IdType="pubmed">31116639</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasta R, Chia R, Traynor BJ, et al. Unraveling the complex interplay between genes, environment, and climate in ALS. eBioMedicine. 2022;75:103795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8728044</ArticleId><ArticleId IdType="pubmed">34974309</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdez G, Tapia JC, Lichtman JW, et al. Shared resistance to aging and ALS in neuromuscular junctions of specific muscles. PLoS ONE. 2012;7:e34640.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3317643</ArticleId><ArticleId IdType="pubmed">22485182</ArticleId></ArticleIdList></Reference><Reference><Citation>Saxena S, Cabuy E, Caroni P. A role for motoneuron subtype&#x2013;selective ER stress in disease manifestations of FALS mice. Nat Neurosci. 2009;12:627&#x2013;636.</Citation><ArticleIdList><ArticleId IdType="pubmed">19330001</ArticleId></ArticleIdList></Reference><Reference><Citation>White MA, Lin Z, Kim E, et al. Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss. Acta Neuropathol Commun. 2019;7:166.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819591</ArticleId><ArticleId IdType="pubmed">31661035</ArticleId></ArticleIdList></Reference><Reference><Citation>Coleman M. Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci. 2005;6:889&#x2013;898.</Citation><ArticleIdList><ArticleId IdType="pubmed">16224497</ArticleId></ArticleIdList></Reference><Reference><Citation>Finn JT, Weil M, Archer F, et al. Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. J Neurosci. 2000;20:1333&#x2013;1341.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6772375</ArticleId><ArticleId IdType="pubmed">10662823</ArticleId></ArticleIdList></Reference><Reference><Citation>Fischer LR, Culver DG, Davis AA, et al. The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis. 2005;19:293&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">15837585</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters OM, Lewis EA, Osterloh JM, et al. Loss of Sarm1 does not suppress motor neuron degeneration in the SOD1G93A mouse model of amyotrophic lateral sclerosis. Hum Mol Genet. 2018;27:3761&#x2013;3771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6196650</ArticleId><ArticleId IdType="pubmed">30010873</ArticleId></ArticleIdList></Reference><Reference><Citation>Puentes F, Malaspina A, van Noort JM, et al. Non-neuronal cells in ALS: role of glial, immune cells and blood-CNS barriers: non-neuronal cells in ALS. Brain Pathol. 2016;26:248&#x2013;257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029111</ArticleId><ArticleId IdType="pubmed">26780491</ArticleId></ArticleIdList></Reference><Reference><Citation>Ademi M, Yang X, Coleman MP, et al. Natural variants of human SARM1 cause both intrinsic and dominant loss-of-function influencing axon survival. Sci Rep. 2022;12:13846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9381744</ArticleId><ArticleId IdType="pubmed">35974060</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali YO, Allen HM, Yu L, et al. NMNAT2:HSP90 complex mediates proteostasis in proteinopathies. PLoS Biol. 2016;14:e1002472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4890852</ArticleId><ArticleId IdType="pubmed">27254664</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti L, Gilley J, Coleman MP. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci. 2014;15:394&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">24840802</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellanos-Montiel MJ, Chaineau M, Durcan TM. The neglected genes of ALS: cytoskeletal dynamics impact synaptic degeneration in ALS. Front Cell Neurosci. 2020;14:594975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7691654</ArticleId><ArticleId IdType="pubmed">33281562</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid E, Kloos M, Ashley-Koch A, et al. A kinesin heavy chain (KIF5A) mutation in hereditary spastic paraplegia (SPG10) Am J Hum Genet. 2002;71:1189&#x2013;1194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC385095</ArticleId><ArticleId IdType="pubmed">12355402</ArticleId></ArticleIdList></Reference><Reference><Citation>Nam DE, Yoo DH, Choi SS, et al. Wide phenotypic spectrum in axonal Charcot&#x2013;Marie&#x2013;Tooth neuropathy type 2 patients with KIF5A mutations. Genes Genom. 2018;40:77&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">29892902</ArticleId></ArticleIdList></Reference><Reference><Citation>Brenner D, Rosenbohm A, Yilmaz R, et al. Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain. 2019;142:e67&#x2013;e67.</Citation><ArticleIdList><ArticleId IdType="pubmed">31612906</ArticleId></ArticleIdList></Reference><Reference><Citation>Duis J, Dean S, Applegate C, et al. KIF5A mutations cause an infantile onset phenotype including severe myoclonus with evidence of mitochondrial dysfunction: KIF5A Mutations. Ann Neurol. 2016;80:633&#x2013;637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5042851</ArticleId><ArticleId IdType="pubmed">27463701</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, van Rheenen W, Goedee HS, et al. Genotype-phenotype correlations of KIF5A stalk domain variants. Amyotroph Lateral Scler Frontotemporal Degener. 2021;22:561&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pubmed">33829936</ArticleId></ArticleIdList></Reference><Reference><Citation>Karle KN, M&#xf6;ckel D, Reid E, et al. Axonal transport deficit in a KIF5A &#x2013;/&#x2013; mouse model. Neurogenetics. 2012;13:169&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3332386</ArticleId><ArticleId IdType="pubmed">22466687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee PJ, Kennedy Z, Wang Y, et al. Imaging net retrograde axonal transport in vivo : a physiological biomarker. Ann Neurol. 2022;91:716&#x2013;729. doi: 10.1002/ana.26329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.26329</ArticleId><ArticleId IdType="pmc">PMC9313858</ArticleId><ArticleId IdType="pubmed">35178738</ArticleId></ArticleIdList></Reference><Reference><Citation>Marinkovi&#x107; P, Reuter MS, Brill MS, et al. Axonal transport deficits and degeneration can evolve independently in mouse models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA. 2012;109:4296&#x2013;4301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3306689</ArticleId><ArticleId IdType="pubmed">22371592</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y-B, Sheng Z-H. Increased axonal mitochondrial mobility does not slow amyotrophic lateral sclerosis (ALS)-like disease in mutant SOD1 mice. J Biol Chem. 2011;286:23432&#x2013;23440.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3123107</ArticleId><ArticleId IdType="pubmed">21518771</ArticleId></ArticleIdList></Reference><Reference><Citation>Riva N, Gentile F, Cerri F, et al. Phosphorylated TDP-43 aggregates in peripheral motor nerves of patients with amyotrophic lateral sclerosis. Brain. 2022;145:276&#x2013;284. doi: 10.1093/brain/awab285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab285</ArticleId><ArticleId IdType="pmc">PMC8967102</ArticleId><ArticleId IdType="pubmed">35076694</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese M, Saal-Bauernschubert L, L&#xfc;ningschr&#xf6;r P, et al. Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathol Commun. 2020;8:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379803</ArticleId><ArticleId IdType="pubmed">32709255</ArticleId></ArticleIdList></Reference><Reference><Citation>Altman T, Ionescu A, Ibraheem A, et al. Axonal TDP-43 condensates drive neuromuscular junction disruption through inhibition of local synthesis of nuclear encoded mitochondrial proteins. Nat Commun. 2021;12:6914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617040</ArticleId><ArticleId IdType="pubmed">34824257</ArticleId></ArticleIdList></Reference><Reference><Citation>Morfini GA, Bosco DA, Brown H, et al. Inhibition of fast axonal transport by pathogenic SOD1 involves activation of p38 MAP kinase. PLoS ONE. 2013;8:e65235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680447</ArticleId><ArticleId IdType="pubmed">23776455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibbs KL, Kalmar B, Rhymes ER, et al. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5964181</ArticleId><ArticleId IdType="pubmed">29789529</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Helleputte L, Kater M, Cook DP, et al. Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth. Neurobiol Dis. 2018;111:59&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">29197621</ArticleId></ArticleIdList></Reference><Reference><Citation>Corradi E, Baudet M-L. In the right place at the right time: miRNAs as key regulators in developing axons. IJMS. 2020;21:8726.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7699167</ArticleId><ArticleId IdType="pubmed">33218218</ArticleId></ArticleIdList></Reference><Reference><Citation>Tosolini AP, Sleigh JN. Intramuscular delivery of gene therapy for targeting the nervous system. Front Mol Neurosci. 2020;13:129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379875</ArticleId><ArticleId IdType="pubmed">32765219</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosanac T, Hughes RO, Engber T, et al. Pharmacological SARM1 inhibition protects axon structure and function in paclitaxel-induced peripheral neuropathy. Brain. 2021;144:3226&#x2013;3238. doi: 10.1093/brain/awab184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awab184</ArticleId><ArticleId IdType="pmc">PMC8634121</ArticleId><ArticleId IdType="pubmed">33964142</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould SA, Gilley J, Ling K, et al. Sarm1 haploinsufficiency or low expression levels after antisense oligonucleotides delay programmed axon degeneration. Cell Rep. 2021;37:110108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8692746</ArticleId><ArticleId IdType="pubmed">34910914</ArticleId></ArticleIdList></Reference><Reference><Citation>Trammell SAJ, Weidemann BJ, Chadda A, et al. Nicotinamide riboside opposes type 2 diabetes and neuropathy in mice. Sci Rep. 2016;6:26933.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882590</ArticleId><ArticleId IdType="pubmed">27230286</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui F, Tang J, Williams PA, et al. Improvement in inner retinal function in glaucoma with nicotinamide (vitamin B3) supplementation: a crossover randomized clinical trial. Clin Experiment Ophthalmol. 2020;48:903&#x2013;914.</Citation><ArticleIdList><ArticleId IdType="pubmed">32721104</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrasekaran K, Choi J, Arvas MI, et al. Nicotinamide mononucleotide administration prevents experimental diabetes-induced cognitive impairment and loss of hippocampal neurons. IJMS. 2020;21:3756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313029</ArticleId><ArticleId IdType="pubmed">32466541</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall K, Farah M. Axonal regeneration and sprouting as a potential therapeutic target for nervous system disorders. Neural Regen Res. 2021;16:1901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8343323</ArticleId><ArticleId IdType="pubmed">33642358</ArticleId></ArticleIdList></Reference><Reference><Citation>Tallon C, Marshall KL, Kennedy ME, et al. Pharmacological BACE inhibition improves axonal regeneration in nerve injury and disease models. Neurotherapeutics. 2020;17:973&#x2013;988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7609814</ArticleId><ArticleId IdType="pubmed">32236823</ArticleId></ArticleIdList></Reference><Reference><Citation>Arthur-Farraj P, Coleman MP. Lessons from injury: how nerve injury studies reveal basic biological mechanisms and therapeutic opportunities for peripheral nerve diseases. Neurotherapeutics. 2021.&#xa0;https://link.springer.com/10.1007/s13311-021-01125-3. Accessed 3 Oct 2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-021-01125-3</ArticleId><ArticleId IdType="pmc">PMC8804063</ArticleId><ArticleId IdType="pubmed">34845709</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>